Volume 23 - Issue 11 - November 2015
Case Report and Brief Review
12/18/2015
Miguel Villacorta, BS; Rogerio Faillace, MD; Elyse Julian, BS; Fawn Winkelman, DO
A 5-year-old girl presented with a 3-week history of multiple discrete, pink, scaly plaques. The plaques were ovoid, ranged from 0.5 to 3 cm in diameter, and were slightly raised, blanchable, and pruritic.
A 5-year-old girl presented with a 3-week history of multiple discrete, pink, scaly plaques. The plaques were ovoid, ranged from 0.5 to 3 cm in diameter, and were slightly raised, blanchable, and pruritic.
A 5-year-old girl presented with...
12/18/2015
The Dermatologist
Derm Dx
12/18/2015
A 57-year-old male with Fitzpatrick skin type III was referred by his primary care physician for the evaluation and management of a newly developed lesion that on exam was consistent with an acrochordon.
A 57-year-old male with Fitzpatrick skin type III was referred by his primary care physician for the evaluation and management of a newly developed lesion that on exam was consistent with an acrochordon.
A 57-year-old male with...
12/18/2015
The Dermatologist
News
12/15/2015
Melanoma patients with preexisting autoimmune disease can be safely treated with ipilimumab (Yervoy, Bristol-Myers Squibb), as long as they are monitored carefully, according to a new study published JAMA Oncology.1
Melanoma patients with preexisting autoimmune disease can be safely treated with ipilimumab (Yervoy, Bristol-Myers Squibb), as long as they are monitored carefully, according to a new study published JAMA Oncology.1
Melanoma patients with...
12/15/2015
The Dermatologist
Coding and Billing
12/03/2015
Lindsay C. Strowd, MD, FAAD
This is a Coding Solutions guest series focusing on dermatology-specific billing, coding and documentation.
This is a Coding Solutions guest series focusing on dermatology-specific billing, coding and documentation.
This is a Coding Solutions guest...
12/03/2015
The Dermatologist
Research in Review
12/02/2015
Mary Lupo, MD
In this guest Cosmetic Clinic column, Dr. Mary Lupo provides excerpts from her July 2015 presentation at the Cosmetic Bootcamp, held in Aspen, CO. She explains how your medical patient is also your next cosmetic patient. ~Kenneth Beer,...
In this guest Cosmetic Clinic column, Dr. Mary Lupo provides excerpts from her July 2015 presentation at the Cosmetic Bootcamp, held in Aspen, CO. She explains how your medical patient is also your next cosmetic patient. ~Kenneth Beer,...
In this guest Cosmetic Clinic...
12/02/2015
The Dermatologist
Research in Review
11/30/2015
Two new FDA approvals for cobimetinib (Cotellic, Roche) and ipilimumab (Yervoy, Bristol-Myers Squibb) for the treatment of melanoma mark the continuing advancement of melanoma research and innovation.
Two new FDA approvals for cobimetinib (Cotellic, Roche) and ipilimumab (Yervoy, Bristol-Myers Squibb) for the treatment of melanoma mark the continuing advancement of melanoma research and innovation.
Two new FDA approvals for...
11/30/2015
The Dermatologist
Research in Review
11/19/2015
Rochelle Nataloni
In Part 4 of this exclusive series, melanoma experts discuss the use of new technology in melanoma detection and treatment.
In Part 4 of this exclusive series, melanoma experts discuss the use of new technology in melanoma detection and treatment.
In Part 4 of this exclusive...
11/19/2015
The Dermatologist
11/19/2015
Lisa B. Samalonis
Many new therapies are in development.
Many new therapies are in development.
Many new therapies are in...
11/19/2015
The Dermatologist
Research in Review
11/17/2015
A review of recent news, research and treatment related to rosacea.
A review of recent news, research and treatment related to rosacea.
A review of recent news,...
11/17/2015
The Dermatologist
11/17/2015
In this excerpt from the recently published book, Practical Psoriasis Management, the authors discuss the use of cyclosporine for acute treatment of severe psoriasis and when other systemic medications have failed.
In this excerpt from the recently published book, Practical Psoriasis Management, the authors discuss the use of cyclosporine for acute treatment of severe psoriasis and when other systemic medications have failed.
In this excerpt from the...
11/17/2015
The Dermatologist
Industry News
11/17/2015
Finacea Foam, 15% is a recently FDA-approved topical treatment for patients experiencing the inflammatory papules and pustules of mild to moderate rosacea.
Finacea Foam, 15% is a recently FDA-approved topical treatment for patients experiencing the inflammatory papules and pustules of mild to moderate rosacea.
Finacea Foam, 15% is a recently...
11/17/2015
The Dermatologist
Research in Review
11/17/2015
Brett Kopelan
As treatment progresses for epidermolysis bullosa, a need for dermatologists who treat adults with the disorder exists.
As treatment progresses for epidermolysis bullosa, a need for dermatologists who treat adults with the disorder exists.
As treatment progresses for...
11/17/2015
The Dermatologist
Board Review
11/17/2015
Bruce Theirs, MD, FAAD
1. Difficulty walking and these conjunctival lesions developed during childhood. Which statement is true?
1. Difficulty walking and these conjunctival lesions developed during childhood. Which statement is true?
1. Difficulty walking and...
11/17/2015
The Dermatologist
Spotlight
11/17/2015
Benjamin Barankin, MD, FRCPC
Dr. Day is a dermatologist who specializes in laser, cosmetic and medical dermatology in New York City.
Dr. Day is a dermatologist who specializes in laser, cosmetic and medical dermatology in New York City.
Dr. Day is a dermatologist...
11/17/2015
The Dermatologist
News
11/17/2015
Lisa B. Samalonis
The Fall conference brought together dermatologists to interact, learn and network.
The Fall conference brought together dermatologists to interact, learn and network.
The Fall conference brought...
11/17/2015
The Dermatologist
News
11/17/2015
The FDA approved the Biologics License Application for Imlygic (talimogene laherparepvec, Amgen), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in...
The FDA approved the Biologics License Application for Imlygic (talimogene laherparepvec, Amgen), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in...
The FDA approved the Biologics...
11/17/2015
The Dermatologist
Chief Medical Editor Message
11/17/2015
Steven R. Feldman, MD, PhD
Humans seek direction. Clearly defined and communicated office policies may help patients get their refills and return appointments in more orderly ways. Clear instructions for why, how and when to use medications — which are not given a...
Humans seek direction. Clearly defined and communicated office policies may help patients get their refills and return appointments in more orderly ways. Clear instructions for why, how and when to use medications — which are not given a...
Humans seek direction. Clearly...
11/17/2015
The Dermatologist
